EGFR and neoplasm: The primary mechanism of TKIs is to target tumor cells harboring activating mutations in the epidermal growth factor receptor (EGFR), a receptor tyrosine kinase of the ErbB family, which plays important roles in sustained tumor cell proliferation [20,21,22].